Aceto Corporation (ACET) News
Filter ACET News Items
ACET News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACET News Highlights
- ACET's 30 day story count now stands at 2.
- Over the past 8 days, the trend for ACET's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO, ADI and SITC are the most mentioned tickers in articles about ACET.
Latest ACET News From Around the Web
Below are the latest news stories about Adicet Bio Inc that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific OfficerMENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer. In this role, Dr. Aftab will be responsible for the continued expansion of Adicet’s pipeline of therapeutic candidates in solid and hematolo |
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual MeetingMENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held November 10-14, 2021. Details of the poster presentation: Title: ADI-002: an IL-15 armored a |
Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer TherapeuticsMENLO PARK, Calif., and BOSTON, MA, and SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, and Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration to accelerate the discover |
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer TherapeuticsSOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON, September 13, 2021--Twist Bioscience and Adicet Bio collaboration to accelerate the discovery of gamma delta T cell therapies against five undisclosed targets |
Adicet Bio to Participate in Upcoming Investor ConferencesMENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in September. Details of the events are as follows: H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021 Registered attendees can access the recorded |
Adicet Reports Second Quarter 2021 Financial Results and Provides Business UpdatesOn track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021MENLO PARK, Calif. and BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the second quarter ended June 30, 2021. “Adicet continues to build momentum over th |
Is Adicet Bio Inc. (ACET) A Good Stock To Buy?Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […] |
Adicet Bio Announces Formation of Scientific Advisory BoardMENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the formation of a Scientific Advisory Board (SAB). The SAB is comprised of renowned scientific leaders in the fields of T cell biology, immunology, and oncology. "We are very pleased to have such distinguished and talented experts join Adicet’s scientific advisory |
Adicet Reports First Quarter 2021 Financial Results and Provides Business UpdatesInitiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021 Successfully raised $143.8 million in net proceeds through a public offering and concurrent private placement to advance a pipeline of CAR gamma-delta T cell therapies MENLO PARK, Calif. and BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the first quarter ended March 31, 2021. “The first quarter of 2021 has been highly productive for Adicet both on the financial and clinical fronts. The successful execution of our capital raise, and the initiation of the ... |
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateReceived IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an anti-CD20 allogeneic CAR gamma-delta T cell therapy, interim clinical data expected in 2021Successfully raised $143.6 million in net proceeds through a public offering and concurrent private placement to advance a pipeline of CAR gamma-delta T cell therapies MENLO PARK, Calif. and BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. “Over the past year, Adicet achieved several development and operational milestones incl... |